More NOAC Comparisons See More Bleeding With Rivaroxaban: Is the ‘Writing on the Wall’?
tctmd.com
Evidence is mounting, albeit from observational studies, that while all of the non-vitamin K antagonist oral anticoagulants (NOACs) appear to have similar efficacy in terms of stroke reduction in atrial fibrillation, they may not be equivalent when it comes to safety.